Welcome

Synthonics Inc. is the global leader in Metal Coordination Pharmaceuticals, with 4 active US Patents and dozens more pending.

Metals have been considered for millennia to have medicinal values. With the advent of modern medicine, many metal-based drugs have proven to be highly effective in the clinic. Many different metal ions have shown activity against a range of diseases. The unique electronic structure of transition metals offers great versatility, not always seen in organic drugs, in terms of the ability to tune the properties of a given molecule (McQuitty).

In September of 2010, the U.S. Patent and Trademark Office issued the first patent in Synthonics’ portfolio. This composition of matter patent, which covers a complex of zinc with triiodothyronine (T3), establishes the patentability of novel molecules created by chelating a metal to a known drug. Synthonics has since definitively demonstrated that Metal Coordination Pharmaceuticals (MCP) can significantly improve a drug’s absorption. The portfolio currently hosts 4 US Patents for MCP technologies with dozens more pending.